
Dx&Vx eyes 1st global licensing deals for mRNA platform, obesity drug, and cancer vaccine
Dx&Vx is closing in on licensing agreements with “multiple pharmaceutical giants” for its room temperature-stable mRNA vaccine platform, the company said Wednesday, marking a pivotal step in its shift from diagnostics to what it now calls a “full-scale …